Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Avalyn Pharma Inc. (AVLN)

$27.95 -5.99% NASDAQ: AVLN · 15-min delayed
  • BOSTON, Massachusetts
  • Public · NASDAQ: AVLN
$1.2BMarket cap
-$26.9MNet income
AVLNNASDAQ
2026IPO

About Avalyn Pharma Inc.

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$26.9M
Total assets
$135.7M
Market cap
$1.2B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: AVLN
$27.95 -5.99%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$25.68 $32.97

52-week range

Market cap
$1.2B
Shares outstanding
42.9M
Open
Day range
Prev close
Volume
IPO date
Apr 30, 2026

Avalyn Pharma Inc. (AVLN) Stock Price

  • Reported a net loss of $26.9M.
  • Trading 15% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Avalyn Pharma Inc..

Write a review
Newsroom

News about Avalyn Pharma Inc.

News & sentiment via Polygon.io

FAQ

Avalyn Pharma Inc.: frequently asked questions

Is Avalyn Pharma Inc. an American company?

Avalyn Pharma Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Avalyn Pharma Inc. headquartered?

Avalyn Pharma Inc. is headquartered in Boston, Massachusetts, United States.

Is Avalyn Pharma Inc. publicly traded?

Yes — Avalyn Pharma Inc. is a publicly traded company. Its stock trades under the ticker symbol AVLN on the NASDAQ.

What does Avalyn Pharma Inc. do?

Avalyn Pharma Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →